Titan Pharmaceuticals is in phase III of its clinical trials for Probuphine, the company’s opiate addiction treatment that, by using its proprietary ProNeura drug delivery system, delivers buprenorphine at a constant, therapeutic level for a period of six months.
Buprenorphine is the partial opiate agonist found in the sublingual pill Suboxone. Probuphine is inserted under the skin in a simple office procedure that requires about fifteen minutes, and thus far, trials have shown a considerable amount of success.
The benefits of a subcutaneous delivery system are that it eliminates or significantly mitigates the inconsistency of compliance, varying levels of the drug in the blood, and the potential for abuse.
Source: Titan Pharmaceuticals
Date: May 5, 2008
Read entire story
More My Addiction News
Sponsored Links
Related Resources
Related Articles
News
Blogs
